The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency

J. Koudy Williams, Delrae Eckman, Ashley Dean, Mahmoudreza Moradi, Julie Allickson, J. Mark Cline, James J. Yoo, Anthony Atala

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Locally injected skeletal muscle precursor cells (skMPCs) integrate into and restore the muscle layers, innervation, vasculature, and function of the sphincter complex in animal models of intrinsic urinary sphincter deficiency (ISD). The goal of the present study was to test the dose-effect safety profile of skMPC therapy in a dog model of ISD. Sphincter deficiency was created in 20 adult female dogs by surgically removing the skeletal muscle layer of the urinary sphincter complex. skMPCs isolated from the hind leg were expanded in culture and injected 4 weeks later into the sphincter complex at a dose of 25 million cells (n = 5), 50 million cells (n = 5), or 100 million cells (n = 5) per milliliter in a 2-ml volume. Five dogs received no sphincter injection. The measures of maximal sphincter pressure, complete blood count, and blood chemistry were performed monthly until their sacrifice at 9 months. At that point, full necropsy was performed to assess the safety of the skMPC injections. Injection of different doses of cells had no effects on the body weight, blood cell count, or kidney or liver function test results (p>.05 among the skMPC doses). Some incidental pathologic features were found in the lower urinary tract in all groups and were most likely associated with repeat catheterization. The maximal urinary sphincter pressure was higher in the 50 million cells per milliliter treatment group than in the other experimental groups (p < .05). The findings of the present study have confirmed that urinary sphincter injection of skMPCs results in no significant local or systemic pathologic features within the dose range thatimproves sphincter pressures.

Original languageEnglish
Pages (from-to)286-294
Number of pages9
JournalStem cells translational medicine
Volume4
Issue number3
DOIs
StatePublished - 2015
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Muscle Cells
Skeletal Muscle
Dogs
Safety
Injections
Blood Cell Count
Pressure
Kidney Function Tests
Liver Function Tests
Urinary Tract
Catheterization
Leg
Animal Models
Body Weight
Muscles
Therapeutics

Keywords

  • Maximal urethral pressure
  • Pathology
  • Skeletal muscle
  • Stem cells
  • Urinary incontinence

ASJC Scopus subject areas

  • Cell Biology
  • Developmental Biology

Cite this

The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency. / Koudy Williams, J.; Eckman, Delrae; Dean, Ashley; Moradi, Mahmoudreza; Allickson, Julie; Mark Cline, J.; Yoo, James J.; Atala, Anthony.

In: Stem cells translational medicine, Vol. 4, No. 3, 2015, p. 286-294.

Research output: Contribution to journalArticle

Koudy Williams, J, Eckman, D, Dean, A, Moradi, M, Allickson, J, Mark Cline, J, Yoo, JJ & Atala, A 2015, 'The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency', Stem cells translational medicine, vol. 4, no. 3, pp. 286-294. https://doi.org/10.5966/sctm.2014-0114
Koudy Williams, J. ; Eckman, Delrae ; Dean, Ashley ; Moradi, Mahmoudreza ; Allickson, Julie ; Mark Cline, J. ; Yoo, James J. ; Atala, Anthony. / The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency. In: Stem cells translational medicine. 2015 ; Vol. 4, No. 3. pp. 286-294.
@article{b4ab629b175441d0a6437c8bd0be80c1,
title = "The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency",
abstract = "Locally injected skeletal muscle precursor cells (skMPCs) integrate into and restore the muscle layers, innervation, vasculature, and function of the sphincter complex in animal models of intrinsic urinary sphincter deficiency (ISD). The goal of the present study was to test the dose-effect safety profile of skMPC therapy in a dog model of ISD. Sphincter deficiency was created in 20 adult female dogs by surgically removing the skeletal muscle layer of the urinary sphincter complex. skMPCs isolated from the hind leg were expanded in culture and injected 4 weeks later into the sphincter complex at a dose of 25 million cells (n = 5), 50 million cells (n = 5), or 100 million cells (n = 5) per milliliter in a 2-ml volume. Five dogs received no sphincter injection. The measures of maximal sphincter pressure, complete blood count, and blood chemistry were performed monthly until their sacrifice at 9 months. At that point, full necropsy was performed to assess the safety of the skMPC injections. Injection of different doses of cells had no effects on the body weight, blood cell count, or kidney or liver function test results (p>.05 among the skMPC doses). Some incidental pathologic features were found in the lower urinary tract in all groups and were most likely associated with repeat catheterization. The maximal urinary sphincter pressure was higher in the 50 million cells per milliliter treatment group than in the other experimental groups (p < .05). The findings of the present study have confirmed that urinary sphincter injection of skMPCs results in no significant local or systemic pathologic features within the dose range thatimproves sphincter pressures.",
keywords = "Maximal urethral pressure, Pathology, Skeletal muscle, Stem cells, Urinary incontinence",
author = "{Koudy Williams}, J. and Delrae Eckman and Ashley Dean and Mahmoudreza Moradi and Julie Allickson and {Mark Cline}, J. and Yoo, {James J.} and Anthony Atala",
year = "2015",
doi = "10.5966/sctm.2014-0114",
language = "English",
volume = "4",
pages = "286--294",
journal = "Stem cells translational medicine",
issn = "2157-6564",
publisher = "AlphaMed Press",
number = "3",

}

TY - JOUR

T1 - The dose-effect safety profile of skeletal muscle precursor cell therapy in a dog model of intrinsic urinary sphincter deficiency

AU - Koudy Williams, J.

AU - Eckman, Delrae

AU - Dean, Ashley

AU - Moradi, Mahmoudreza

AU - Allickson, Julie

AU - Mark Cline, J.

AU - Yoo, James J.

AU - Atala, Anthony

PY - 2015

Y1 - 2015

N2 - Locally injected skeletal muscle precursor cells (skMPCs) integrate into and restore the muscle layers, innervation, vasculature, and function of the sphincter complex in animal models of intrinsic urinary sphincter deficiency (ISD). The goal of the present study was to test the dose-effect safety profile of skMPC therapy in a dog model of ISD. Sphincter deficiency was created in 20 adult female dogs by surgically removing the skeletal muscle layer of the urinary sphincter complex. skMPCs isolated from the hind leg were expanded in culture and injected 4 weeks later into the sphincter complex at a dose of 25 million cells (n = 5), 50 million cells (n = 5), or 100 million cells (n = 5) per milliliter in a 2-ml volume. Five dogs received no sphincter injection. The measures of maximal sphincter pressure, complete blood count, and blood chemistry were performed monthly until their sacrifice at 9 months. At that point, full necropsy was performed to assess the safety of the skMPC injections. Injection of different doses of cells had no effects on the body weight, blood cell count, or kidney or liver function test results (p>.05 among the skMPC doses). Some incidental pathologic features were found in the lower urinary tract in all groups and were most likely associated with repeat catheterization. The maximal urinary sphincter pressure was higher in the 50 million cells per milliliter treatment group than in the other experimental groups (p < .05). The findings of the present study have confirmed that urinary sphincter injection of skMPCs results in no significant local or systemic pathologic features within the dose range thatimproves sphincter pressures.

AB - Locally injected skeletal muscle precursor cells (skMPCs) integrate into and restore the muscle layers, innervation, vasculature, and function of the sphincter complex in animal models of intrinsic urinary sphincter deficiency (ISD). The goal of the present study was to test the dose-effect safety profile of skMPC therapy in a dog model of ISD. Sphincter deficiency was created in 20 adult female dogs by surgically removing the skeletal muscle layer of the urinary sphincter complex. skMPCs isolated from the hind leg were expanded in culture and injected 4 weeks later into the sphincter complex at a dose of 25 million cells (n = 5), 50 million cells (n = 5), or 100 million cells (n = 5) per milliliter in a 2-ml volume. Five dogs received no sphincter injection. The measures of maximal sphincter pressure, complete blood count, and blood chemistry were performed monthly until their sacrifice at 9 months. At that point, full necropsy was performed to assess the safety of the skMPC injections. Injection of different doses of cells had no effects on the body weight, blood cell count, or kidney or liver function test results (p>.05 among the skMPC doses). Some incidental pathologic features were found in the lower urinary tract in all groups and were most likely associated with repeat catheterization. The maximal urinary sphincter pressure was higher in the 50 million cells per milliliter treatment group than in the other experimental groups (p < .05). The findings of the present study have confirmed that urinary sphincter injection of skMPCs results in no significant local or systemic pathologic features within the dose range thatimproves sphincter pressures.

KW - Maximal urethral pressure

KW - Pathology

KW - Skeletal muscle

KW - Stem cells

KW - Urinary incontinence

UR - http://www.scopus.com/inward/record.url?scp=84923418766&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923418766&partnerID=8YFLogxK

U2 - 10.5966/sctm.2014-0114

DO - 10.5966/sctm.2014-0114

M3 - Article

AN - SCOPUS:84923418766

VL - 4

SP - 286

EP - 294

JO - Stem cells translational medicine

JF - Stem cells translational medicine

SN - 2157-6564

IS - 3

ER -